Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913639 | 0.80 | KEAP1 (0.57) | KCNN4KEAP1NFE2L2CHRM3ALDH1A1 | |
| SCHEMBL2062827 | 0.80 | KEAP1 (0.57) | KCNN4KEAP1NFE2L2CHRM3ALDH1A1 | |
| SCHEMBL2062807 | 0.79 | KEAP1 (0.70) | KEAP1NFE2L2CHRM3ALDH1A1CHRM2 | |
| SCHEMBL522945 | 0.79 | KEAP1 (0.70) | KEAP1NFE2L2CHRM3ALDH1A1CHRM2 | |
| SCHEMBL4208886 | 0.79 | CHRM3 (0.64) | KCNN4KEAP1NFE2L2CHRM3ALDH1A1 | |
| SCHEMBL2655676 | 0.79 | CHRM3 (0.64) | KCNN4KEAP1NFE2L2CHRM3ALDH1A1 | |
| SCHEMBL2763726 | 0.79 | KEAP1 (0.56) | KCNN4KEAP1NFE2L2CHRM3ALDH1A1 | |
| SCHEMBL1234889 | 0.79 | KEAP1 (0.70) | KEAP1NFE2L2CHRM3ALDH1A1CHRM2 | |
| SCHEMBL5262791 | 0.77 | KEAP1 (0.50) | KCNN4KEAP1NFE2L2CHRM3ALDH1A1 | |
| SCHEMBL1610849 | 0.77 | KEAP1 (0.68) | KEAP1NFE2L2CHRM3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364479-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| US-8846954-B2 | Crystallisation and purification of glycopyrronium bromide | SOSEI R&D LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| EP-2580194-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | Chiesi Farmaceutici S.p.A. (IT) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011157536-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-22 | — | — | WO | disclosed |
| US-20110306650-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-15 | — | — | US | disclosed |
| US-7915303-B2 | Glycopyrronium salts and their therapeutic use | SOSEI R&D LTD. (GB) | 2011-03-29 | — | — | US | disclosed |
| EP-1856041-B1 | CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE | SOSEI R & D LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-20090062372-A1 | Glycopyrronium Salts and Their Therapeutic Use | HEPTARES THERAPEUTICS LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080227988-A1 | Reaction of glycopyrronium base with methyl bromide in solvent selected such that diastereoisomeric ratio of product favors R, S and S, R diastereoisomers over R, R, and S, S diastereoisomers, and separating desired diastereoisomers by controlled crystallisation steps; narrow particle size distribution | HEPTARES THERAPEUTICS LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1861361-A1 | GLYCOPYRRONIUM SALTS AND THEIR THERAPEUTIC USE | Sosei R&D Ltd. (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1856041-A1 | CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE | Sosei R&D Ltd. (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006100453-A1 | GLYCOPYRRONIUM SALTS AND THEIR THERAPEUTIC USE | SOSEI R & D LTD. (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006092617-A1 | CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE | SOSEI R & D LTD. (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227988-A1 | Reaction of glycopyrronium base with methyl bromide in solvent selected such that diastereoisomeric ratio of product favors R, S and S, R diastereoisomers over R, R, and S, S diastereoisomers, and separating desired diastereoisomers by controlled crystallisation steps; narrow particle size distribution | TSHR, GYPA, GLRB | KCNN4 2884/4885KEAP1 4881/4885NFE2L2 4873/4885 |
| US-20090062372-A1 | Glycopyrronium Salts and Their Therapeutic Use | TPO, THRB, GYPA | KCNN4 379/4885KEAP1 4782/4885NFE2L2 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.